In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

William Looney

Executive Editor

New York, NY
Advertisement
Set Alert for Articles By William Looney

Latest From William Looney

ImmunoGen’s Mark Enyedy On Striking Deals – And Curing Cancer

Veteran biopharma deal-maker Mark Enyedy has a new role as CEO of ImmunoGen, currently an investor favorite – company shares are up nearly 200% this year. In this interview he discusses corporate restructuring, the evolving role of business development and making new scientific inroads against hard-to-treat cancers.

BioPharmaceutical Deals

Halozyme’s “Hat Collector” Approach To Human Capital: Virtue in Versatility

A Q&A on biopharma workforce recruitment, training and C-suite oversight with Halozyme's Ken Schultz, MD. A supplement to our feature on the In Vivo/EBD Academy survey, "Future-Proofing Human Capital in the Global Life Sciences: Does Biopharma Have the Right Stuff?

BioPharmaceutical Leadership

Biopharma Talent Hunt: Top C-suite Recruiter Mulls The Next Generation Of Leaders

An interview with Odgers Berndtson's John Hawkins about the credentials needed for the next-gen biopharma C-suite. A supplement to our feature on the In Vivo/EBD Academy survey, “Future-Proofing Human Capital: Does Biopharma Have the Right Stuff?”

Business Strategies Leadership

Infographic: Human Capital In Biopharma

A sampling of data from In Vivo and the EBD Academy's comprehensive survey, Future-Proofing Human Capital In Global Life Sciences.

BioPharmaceutical Leadership

Takeda’s Take On The Future Of Biopharma Human Capital

In this supplement to our feature on the In Vivo/EBD Academy survey "Future-Proofing Human Capital In Global Life Sciences", Ramona Sequeira, President of Takeda Pharmaceutical's US Business Unit, presents her company’s strategy to anticipate and respond to a disruptive transformation of the industry payer base.

Business Strategies Leadership

Future-Proofing Human Capital: Does Biopharma Have The Right Stuff?

Biopharma's future depends entirely on the application of human ingenuity to complex problems with no easy solutions. In Vivo, with its Informa business solutions partner EBD Academy, recently conducted a survey of industry decision-makers in the US and Europe for recommendations on how to attract talent, boost employee engagement, foster diversity and maintain the product innovation that patients demand and society expects.

BioPharmaceutical Leadership
See All
Advertisement
UsernamePublicRestriction

Register